Skip to main content
logo
Avience Biomedicals Limited (NSE:AVIENCE)
India flag India · Delayed Price · Currency is INR
287.40
-2.75 (-0.95%)
At close: Oct 7, 2026

Avience Biomedicals Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
525.16525.16453.5239.64109.26101.48
Revenue Growth
417.53%15.80%89.24%119.32%7.68%795.59%
Gross Profit
236.08236.08182.383.2831.3726.35
Operating Income
138.83138.83111.2938.212.2211.21
Net Income
87.5387.5370.9921.527.767.13
Earnings Per Share
21.7121.7118.716.552.915.30
EPS Growth
309.91%16.04%185.67%125.41%-45.14%-30.40%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
29.3429.3449.373.572.450.25
Total Debt
289.35289.35221.58151.3126.5724.88
Net Cash (Debt)
-260-260-172.22-147.74-24.12-24.64
Net Cash Growth
------
Net Cash Per Share
-64.50-64.50-45.39-44.98-9.04-18.31

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
59.0659.0633.949.8515.87-19.63
Capital Expenditures
-134.49-134.49-92.99-38.81-16.88-8.69
Free Cash Flow
-75.42-75.42-59.04-28.96-1.01-28.31
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
44.95%44.95%40.20%34.75%28.71%25.97%
Operating Margin
26.43%26.43%24.54%15.94%11.18%11.05%
Pretax Margin
23.74%23.74%21.54%12.35%8.78%9.48%
Profit Margin
16.67%16.67%15.65%8.98%7.10%7.02%
FCF Margin
-14.36%-14.36%-13.02%-12.08%-0.92%-27.90%